Clinical Trials
59 trialsDonor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Institutes of Health Clinical Center (CC)
FCR
Hackensack Meridian Health
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
ICLL07GAI
French Innovative Leukemia Organisation
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
iFCR
Dana-Farber Cancer Institute
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-KOE-001
Baptist Health South Florida
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
M.D. Anderson Cancer Center
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
M.D. Anderson Cancer Center
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
MT2009-15
Masonic Cancer Center, University of Minnesota
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Hoffmann-La Roche
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Tandem Auto-Allo Transplant for Lymphoma
Massachusetts General Hospital
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
German CLL Study Group
ECO-1
Sanofi
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
University of Pittsburgh
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Pilot Study of Unrelated Cord Blood Transplantation
King's College Hospital NHS Trust
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Stanford University